Product logins

Find logins to all Clarivate products below.


Postoperative Pain | Current Treatment: Physician Insights | US | 2019

A variety of analgesic products are available to specialists managing postoperative pain in the United States, although the majority of these medicines are available as inexpensive generics. Physicians generally rely on multimodal therapy to manage acute postoperative pain, layering drugs in different analgesic classes (e.g., an NSAID / acetaminophen and an opioid), in an attempt to minimize side effects and reduce opioid consumption. Branded products, such as AcelRx’s Dsuvia, Mallinckrodt’s Ofirmev, and Pacira’s Exparel, face market uptake obstacles including hospital adoption and reimbursement constraints. Given the shifting trends in the management of postoperative pain, understanding the treatment algorithm and prescribing drivers is important for marketers of current branded products, as well as developers of emerging therapies.

QUESTIONS ANSWERED

  •  Which drug classes and agents are used most often for postoperative pain, and in which stages of treatment (intraoperative, postoperative, at discharge) are they administered / prescribed?
  • Which drug formulations are most popular at the different stages of treatment, and which physician type (surgical specialist or anesthesiologist) is most involved in prescribing / administering at each stage?
  • How do physicians characterize recent changes in their treatment of postoperative pain, and what changes to current usage do they expect within the next year?
  • What drives physicians to prescribe / administer select branded therapies, and what are the key obstacles holding them back from using these products?

GEOGRAPHY

 United States

PRIMARY RESEARCH

Survey of 50 anesthesiologists, 41 surgical specialists, and 11 orthopedic surgeons.

KEY DRUGS COVERED

Dsuvia, Nucynta IR / ER, Sprix, Caldolor, Ofirmev, Exparel, generic oral and parenteral opioids, NSAIDs / acetaminophen, and local anesthetics.

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.

Related Market Assessment Reports

Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Dry Eye – Current Treatment – Current Treatment: Physician Insights – Dry Eye Disease (EU3)
Dry eye disease (DED) is characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. In Europe, DED has traditionally been managed…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…